Clinical calculator summary
Original 2010 Moore/GOG Cervical Prognostic Index
Clinical calculator summary
Original 2010 Moore/GOG Cervical Prognostic Index
A five-factor historical prognostic index with equal one-point weights.
Evidence-based context for fast calculator use
- Purpose:
- Reproduce the source-defined GOG risk grouping and historical cohort outcomes without turning them into treatment advice.
- Population:
- Adults with measurable stage IVB, persistent, or recurrent cervical carcinoma in a cisplatin-containing combination chemotherapy context.
- Factors:
- Historical race variable, GOG performance status, Measurable pelvic disease, Prior radiosensitizing chemotherapy, Recurrence or progression within one year
- Reference:
- Moore et al. Gynecol Oncol. 2010;116(1):44-49.
Pin your most used calculators here by clicking the star in the dropdown.
Moore/GOG Cervical Prognostic Index
Clinical Context & Background
This calculator implements the original 2010 Moore/Gynecologic Oncology Group prognostic index for adults with stage IVB, persistent, or recurrent measurable cervical carcinoma receiving cisplatin-containing combination chemotherapy. One point is assigned for each of five historical factors: the Black race variable recorded in the GOG dataset, GOG performance status 1-2, measurable pelvic disease, prior radiosensitizing chemotherapy, and first recurrence or progression within one year of diagnosis.
Scores 0-1, 2-3, and 4-5 form low-, mid-, and high-risk groups. Historical derivation-cohort median progression-free survival was 6.34, 4.60, and 2.79 months, and median overall survival was 11.10, 9.17, and 5.49 months, respectively. These are cohort observations from older cisplatin-era trials, not current individualized predictions.
The historical Black/non-Black variable is a social and demographic dataset variable, not a biological determinant. Do not infer it from ethnicity, nationality, ancestry, appearance, or genetic data. The score does not select a regimen, bevacizumab, immunotherapy, or another treatment, and modern outcomes may differ substantially.
Formula Logic
Original 2010 Moore/GOG prognostic index: add 1 point for each of five factors - the historical Black race variable, GOG performance status 1-2, measurable pelvic disease, prior radiosensitizing chemotherapy, and first recurrence or progression within one year of diagnosis. Scores 0-1 are low, 2-3 mid, and 4-5 high.Reference Data
| Group | Score | Historical median PFS / OS |
|---|---|---|
| Low risk | 0-1 | 6.34 / 11.10 months |
| Mid risk | 2-3 | 4.60 / 9.17 months |
| High risk | 4-5 | 2.79 / 5.49 months |
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
When To Use
- Use only after confirming measurable stage IVB, persistent, or recurrent cervical carcinoma and the historical cisplatin-containing combination treatment context.
- Use GOG performance status and explicitly assessed source factors; do not infer the race variable.
How To Interpret
- Scores 0-1, 2-3, and 4-5 map to low, mid, and high historical prognostic groups.
- Treat PFS and OS values as historical cohort observations rather than personalized forecasts.
What To Do Next
- Integrate current pathology, imaging, biomarkers, performance status, patient goals, contemporary guidelines, and multidisciplinary review.
- Do not use the score alone to choose or withhold systemic therapy.
Limitations
- The model comes from older cisplatin-era GOG trial populations and was predominantly studied in squamous carcinoma.
- It is not applicable to localized disease, nonmeasurable disease, GOG PS 3-4, pediatric patients, or a different treatment context.
- The historical race variable has important social, ethical, and transportability limitations.
Validated Population
Adults with measurable stage IVB, persistent, or recurrent cervical carcinoma treated in the source GOG cisplatin-combination trial context.
Calculation verification history
Verified
Calculation verification history
Verified: Production browser revalidation
- Three source-backed cases passed through visible production controls at scores 0, 2, and 5 across all risk groups.
- The former completed-visible-controls rejection was absent; numeric performance-status selections were accepted normally.
- No unexpected N/A, literal undefined value, stale control, unsupported gauge, or browser-console error was observed.
Case-level evidence is retained in validation/browser-revalidation/moore-cervical-2026-08-03.json.
: Local browser remediation verified; production retest pending
- Updated the compact browser adapter to accept exact numeric select/radio values while preserving the original five-factor engine.
- Ten local visible-browser cases passed across scores 0-5, low/mid/high groups, outside-population PS, required-field feedback, and reset/repeat behavior.
- The production finding remains open until deployment and public revalidation.
Local diagnostic evidence is retained in validation/browser-production/moore-cervical.local-remediation.json.
: Production browser validation found a calculation-path defect
- Nine of ten planned browser cases failed: every fully completed visible profile across scores 0 through 5 rendered N/A / Invalid Input, and GOG PS 3 also failed its expected not-applicable disposition.
- A supplemental reproduction confirmed all four radio controls and GOG PS 0 visibly retained their selections immediately before submission, excluding an omitted or stale control as the explanation.
- Missing-DFI validation and reset clearing passed, but maximum-score and zero-score calculations remained invalid; production also emitted React hydration error #418.
Exact case-level reproductions are retained in validation/browser-production/moore-cervical.json.
: Input workflow simplified and revalidated
- Reduced the public form to result-, branch-, unit-, and applicability-changing inputs; removed or consolidated non-scoring, administrative, and duplicate questions.
- Preserved the verified calculation or report-interpretation logic, thresholds, model version, component logic, and supported result pathways behind strict deterministic adapters.
- Passed the calculator-specific regression audit, adapter-parity and malformed-input checks, the 144-calculator input-quality audit, and the 43-calculator entry-burden audit.
: Full validation test
- 256/256 source-factor, exhaustive combination, applicability, malformed-input, UI, trace, wording, report, registry, and isolation checks passed.
- No registered master panel calculates this Moore/GOG index; no panel receives inherited verification.
: Calculation and input-contract correction
- Replaced defaulted point-coded inputs and Object.values coercion with eight explicit fields, five equal source factors, strict missing/extra/type validation, and separate not-applicable outcomes.
- Corrected historical PFS and OS medians, clarified measurable pelvic disease and diagnosis-to-recurrence timing, removed regimen-selection wording, and added limitations for the historical race variable and older treatment era.
Verification confirms the calculator implementation against the cited model; it is not independent clinical validation, regulatory approval, or medical advice.
Related Tools
Frequently Asked Questions
Does this score choose a chemotherapy or immunotherapy regimen?
No. It reproduces a historical prognostic grouping and does not personalize or select treatment.
How should the race variable be interpreted?
It reproduces the Black/non-Black variable recorded in the historical GOG dataset. It is not a biological determinant and must not be inferred from appearance, ancestry, nationality, ethnicity, or genetic data.
Are the displayed survival medians individual predictions?
No. They are historical derivation-cohort medians from older cisplatin-era trials and may not represent outcomes with current therapy.
Evidence-based oncology decision support. Verify with clinical guidelines.